|
|
|
|
|
|
|
|
|
|
[News] US firm corners exclusive license for RAD51C cancer gene:
"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C, under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.